Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.64 |
| ▸ | FABP5 | Q01469 | 3/20 | 0.50 |
| ▸ | FABP7 | O15540 | 2/20 | 0.50 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.45 |
| ▸ | CASP3 | P42574 | 2/20 | 0.43 |
| ▸ | CA1 | P00915 | 1/20 | 0.43 |
| ▸ | CA2 | P00918 | 1/20 | 0.43 |
| ▸ | EGFR | P00533 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | MGLL | Q99685 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5972005 | 0.95 | KMT2A (0.70) | KMT2AFABP5FABP7EPHX2CASP3 | |
| SCHEMBL2401694 | 0.95 | KMT2A (0.70) | KMT2AFABP5FABP7EPHX2CASP3 | |
| SCHEMBL7565247 | 0.94 | KMT2A (0.58) | KMT2AFABP5FABP7EPHX2CASP3 | |
| SCHEMBL3623157 | 0.94 | KMT2A (0.55) | KMT2AFABP5FABP7EPHX2CASP3 | |
| SCHEMBL5497609 | 0.91 | KMT2A (0.59) | KMT2AFABP5FABP7EPHX2CASP3 | |
| SCHEMBL31378081 | 0.91 | KMT2A (0.59) | KMT2AFABP5FABP7EPHX2CASP3 | |
| SCHEMBL14759878 | 0.89 | KMT2A (0.60) | KMT2AFABP5FABP7EPHX2CASP3 | |
| SCHEMBL12440444 | 0.89 | KMT2A (0.58) | KMT2AFABP5FABP7EPHX2CASP3 | |
| SCHEMBL5497604 | 0.87 | KMT2A (0.55) | KMT2AFABP5FABP7EPHX2CASP3 | |
| SCHEMBL16256821 | 0.87 | KMT2A (0.49) | KMT2AFABP5FABP7EPHX2CASP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 51 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170035906-A1 | (ANTI-HER2 ANTIBODY)-DRUG CONJUGATE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2017-02-09 | — | — | US | disclosed |
| US-9409952-B2 | Peptide-compound cyclization method | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2016-08-09 | — | — | US | disclosed |
| US-9267949-B2 | Alkylamino BODIPY dyes as selective fluorescent probes for proteins and mouse embryonic stem cells | NATIONAL UNIVERSITY OF SINGAPORE (SG) | 2016-02-23 | — | — | US | disclosed |
| US-20150167055-A1 | FUNCTIONAL MOLECULE, FUNCTIONAL MOLECULE SYNTHESIZING AMIDITE AND TARGET SUBSTANCE ANALYSIS METHOD | APTA BIOSCIENCES LTD. (GB) | 2015-06-18 | — | — | US | disclosed |
| US-8895231-B2 | Patterning process and resist composition | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2014-11-25 | — | — | US | disclosed |
| US-20140121129-A1 | Alkylamino BODIPY Dyes As Selective Fluorescent Probes For Proteins And Mouse Embryonic Stem Cells | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2014-05-01 | — | — | US | disclosed |
| US-8524691-B2 | Phosphonated rifamycins and uses thereof for the prevention and treatment of bone and joint infections | THE MEDICINES COMPANY (US) | 2013-09-03 | — | — | US | disclosed |
| US-8288516-B2 | Functional molecule, functional molecule synthesizing amidite and target substance analysis method | FUJITSU LIMITED (JP) | 2012-10-16 | — | — | US | disclosed |
| US-8288516-B2 | Functional molecule, functional molecule synthesizing amidite and target substance analysis method | FUJITSU LIMITED (JP) | 2012-10-16 | — | — | US | disclosed |
| US-20120058428-A1 | PATTERNING PROCESS AND RESIST COMPOSITION | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2012-03-08 | — | — | US | disclosed |
| US-6355611-B1 | SODIUM SALT OF PROSTATE SPECIFIC ANTIGEN CONJUGATE COMPOUND; USEFUL IN TREATMENT OF PROSTATE CANCER AND BENIGN PROSTATIC HYPERPLASIA | MERCK & CO., INC. | 2002-03-12 | — | — | US | disclosed |
| WO-2001030804-A2 | SALT FORM OF A CONJUGATE USEFUL IN THE TREATMENT OF PROSTATE CANCER | MERCK & CO., INC. (US) | 2001-05-03 | — | — | WO | disclosed |
| WO-2001029065-A1 | PROCESS FOR PREPARING PEPTIDE INTERMEDIATES | MERCK SHARP & DOHME LIMITED (GB) | 2001-04-26 | — | — | WO | disclosed |
| WO-2001028593-A2 | CONJUGATES USEFUL IN THE TREATMENT OF PROSTATE CANCER | MERCK & CO., INC. (US) | 2001-04-26 | — | — | WO | disclosed |
| EP-1060189-A1 | DERIVATIVES OF GLYCOPEPTIDE ANTIBACTERIAL AGENTS | Advanced Medicine, Inc. (US) | 2000-12-20 | — | — | EP | disclosed |
| WO-1999042476-A1 | NOVEL ANTIBACTERIAL AGENTS | ADVANCED MEDICINE, INC. (US) | 1999-08-26 | — | — | WO | disclosed |
| US-5886177-A | ETHYLENE GLYCOL MONOMERS JOINED VIA STANDARD PHOSPHATE LINKAGES INCLUDING PHOSPHOROTHIOATE, PHOSPHODIESTER, AND PHOSPHORAMIDATE LINKAGES; USEFUL FUNCTIONAL GROUPS INCLUDE NUCLEOBASES AS WELL AS POLAR GROUPS, HYDROPHOBIC GROUPS | ISIS PHARMACEUTICALS, INC. (US) | 1999-03-23 | — | — | US | disclosed |
| EP-0739351-A4 | MONOMERIC DIOLS AND PHOSPHATE LINKED OLIGOMERS FORMED THEREFROM | ISIS PHARMACEUTICALS INC (US) | 1998-10-21 | — | — | EP | disclosed |
| EP-0739351-A1 | MONOMERIC DIOLS AND PHOSPHATE LINKED OLIGOMERS FORMED THEREFROM | ISIS PHARMACEUTICALS, INC. (US) | 1996-10-30 | — | — | EP | disclosed |
| WO-1995018820-A1 | MONOMERIC DIOLS AND PHOSPHATE LINKED OLIGOMERS FORMED THEREFROM | ISIS PHARMACEUTICALS, INC. (US) | 1995-07-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170035906-A1 | (ANTI-HER2 ANTIBODY)-DRUG CONJUGATE | ERBB2, EGFR, LANCL2 | KMT2A 506/4885FABP5 2182/4885FABP7 2483/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.